GA
SRPT icon

Geneva Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Geneva Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,615
Closed -$1.08M – 802
2016
Q3 		$1.08M Buy
+17,615
New +$533K 0.02% 299

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geneva Advisors's SRPT Position: Q4 2016 in Review

Geneva Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2016, closing a stake of 17,615 shares — an estimated $1.08M sold.

Geneva Advisors first reported a position in SRPT in Q3 2016 and held it in 1 quarter. The position peaked at $1.08M in Q3 2016. 177 funds tracked by Wall St. Rank hold SRPT as of Q4 2016.

  • Geneva Advisors reported no remaining Sarepta Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Geneva Advisors sold 17,615 Sarepta Therapeutics shares in Q4 2016, an estimated $1.08M.
  • Geneva Advisors first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 1 quarter.
  • Geneva Advisors's Sarepta Therapeutics position peaked at $1.08M in Q3 2016.
  • 177 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2016.

Based on Geneva Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.